Trials & R&D · first seen yesterday, updated yesterday

Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags

1 outlet CAR-T & cell therapy

As two Big Pharma players in the autoimmune CAR-T space face unexpected safety setbacks, Kyverna Therapeutics is reporting long-term clinical data that showcase sustained efficacy alongside an unblemished safety profile for its potential fi…

Summary from Fierce Biotech - Biotech.

Coverage 1 article · 1 outlet

Fierce Biotech - Biotech yesterday
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags